Ignite Creation Date:
2024-07-17 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06487078
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-05
First Post:
2024-06-05
Brief Title:
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
Sponsor:
Pfizer
Organization:
Pfizer
Conditions & Keywords Data
Conditions:
| Name |
|---|
| ALK Non-Small-Cell Lung Carcinoma |
Keywords: